Effect of iron deficiency anemia on the levels of hemoglobin A1c in nondiabetic patients
Effect of iron deficiency anemia on the levels of hemoglobin A1c in nondiabetic patients
复制标题
DOI：
10.1159/000079722
复制
发表时间：
2004-01-01
影响因子：
2.4
通讯作者：
Timuragaoglu, A
中科院分区：
文献类型：
--
作者：
Coban, E;Ozdogan, M;Timuragaoglu, A
糖化血红蛋白的主要形式是血红蛋白A1c(HbA1c)。糖化血红蛋白在慢性高血糖糖尿病患者中异常升高，并与血糖控制呈正相关。以往的研究表明，缺铁性贫血(IDA)会影响HbA1c水平。本研究的目的是确定IDA对非糖尿病患者HbA1c水平的影响。研究人群包括50名IDA患者(30名女性，20名男性，平均年龄35.7±11.9岁)和50名年龄和性别匹配的健康受试者。有糖耐量异常(糖耐量受损或糖尿病)、血红蛋白疾病、溶血性贫血、慢性酒精摄入和慢性肾功能衰竭的患者被排除在研究之外。所有受试者在铁剂治疗前都进行了血液学检查、空腹和餐后血糖和糖化血红蛋白水平的测定。所有IDA患者均服用铁剂100 mg/d，疗程3个月。铁剂治疗后，我们重复了实验室检查。铁治疗前，缺铁性贫血患者的HbA1c平均水平(7.4%+/-0.8%)高于健康组(5.9%+/-0.5%)(p<；0.001)。缺铁性贫血患者的糖化血红蛋白在铁治疗后显著下降，从平均7.4%+/-0.8降至6.2%+/-0.6(p<；0.001)。在根据糖化血红蛋白做出任何诊断或治疗决定之前，必须纠正缺铁。版权所有(C)2004 S.Karger AG，巴塞尔。
The major form of glycohemoglobin is hemoglobin A1c (HbA1c). The HbA1c fraction is abnormally elevated in chronic hyperglycemic diabetic patients and correlates positively with glycemic control. Previous studies suggest that iron deficiency anemia (IDA) affects the levels of HbA1c. The aim of this study was to determine the effect of IDA on HbA1c levels in nondiabetic patients. The population studied consisted of 50 patients ( 30 women, 20 men, mean age 35.7 +/- 11.9 years) with IDA and 50 healthy subjects that were matched for age and sex. Patients who had glucose tolerance abnormalities ( impaired glucose tolerance or diabetes mellitus), hemoglobinopathies, hemolytic anemia, chronic alcohol ingestion and chronic renal failure were excluded from the study. Hematologic investigations, fasting and postprandial glucose and HbA1c levels were measured in all subjects before iron therapy. All patients with IDA were treated with iron 100 mg/day for 3 months. We repeated the laboratory investigation after iron therapy. Before iron treatment, the mean HbA1c (7.4 +/- 0.8%) level in patients with IDA was higher than in a healthy group (5.9% +/- 0.5) ( p < 0.001). In patients with IDA, HbA1c decreased significantly after iron treatment from a mean of 7.4% +/- 0.8 to 6.2% +/- 0.6 ( p < 0.001). Iron deficiency must be corrected before any diagnostic or therapeutic decision is made based on HbA1c. Copyright (C) 2004 S. Karger AG, Basel.